Mycophenolate mofetil
- CAS No.
- 128794-94-5
- Chemical Name:
- Mycophenolate mofetil
- Synonyms
- TM-MMF;Linfonex;RS 61443;Nsc724229;AKOS 92025;Mycophenolate;MYCOPHENLATE MOFETIL;Mycophenolate mofetil;Mofetil mycophenolate;Macophenolate Mofetil
- CBNumber:
- CB5663336
- Molecular Formula:
- C23H31NO7
- Molecular Weight:
- 433.49
- MOL File:
- 128794-94-5.mol
- MSDS File:
- SDS
- Modify Date:
- 2023/11/16 20:18:48
| Melting point | 95-96°C |
|---|---|
| Boiling point | 637.6±55.0 °C(Predicted) |
| Density | 1.222±0.06 g/cm3(Predicted) |
| storage temp. | room temp |
| solubility | DMSO: ≥15mg/mL |
| form | powder |
| pka | 5.6(at 25℃) |
| color | white to beige |
| Merck | 14,6327 |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
| InChIKey | RTGDFNSFWBGLEC-SYZQJQIISA-N |
| CAS DataBase Reference | 128794-94-5(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS07,GHS08,GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H302-H360D-H372-H410 | |||||||||
| Precautionary statements | P202-P260-P264-P273-P301+P312-P308+P313 | |||||||||
| Hazard Codes | Xn | |||||||||
| Risk Statements | 22 | |||||||||
| Safety Statements | 22-24/25 | |||||||||
| RIDADR | UN 3077 9 / PGIII | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | MP7746700 | |||||||||
| HS Code | 29349990 | |||||||||
| NFPA 704 |
|
Mycophenolate mofetil price More Price(5)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML0284 | Mycophenolate mofetil ≥98% (HPLC) | 128794-94-5 | 10MG | ₹4687.23 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SML0284 | Mycophenolate mofetil ≥98% (HPLC) | 128794-94-5 | 50MG | ₹15869.45 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1451 | Mycophenolate Mofetil Pharmaceutical Secondary Standard; Certified Reference Material | 128794-94-5 | 1G | ₹22516 | 2022-06-14 | Buy |
| TCI Chemicals (India) | M2387 | Mycophenolate Mofetil | 128794-94-5 | 100MG | ₹2000 | 2022-05-26 | Buy |
| TCI Chemicals (India) | M2387 | Mycophenolate Mofetil | 128794-94-5 | 1G | ₹7400 | 2022-05-26 | Buy |
Mycophenolate mofetil Chemical Properties,Uses,Production
Description
Mycophenolate mofetil was launched in 1995 in the U.S.A., its first market worldwide, for the prevention of acute kidney transplant rejection in conjunction with other immunosuppressive therapy and to treat refractory acute kidney graft rejection. With improved oral absorption and bioavailability, mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), a fermentation product of several Penicillium species. MPA is a selective, reversible, non-competitive inhibitor of inosinate dehydrogenase and guanylate synthetase. It inhibits the de now pathway of purine biosynthesis. MPA was found to have more potent antiproliferative effects on T and B lymphocytes than other cell types. Compared with other immunosuppressants, mycophenolate mofetil is reportedly superior due to its unique mechanism of action and excellent safety profile for long term use. Mycophenolate mofetil is being investigated clinically in the treatment of heart and liver transplantation rejection, asthma, in preventing coronary artery restenosis, and in treating rheumatoid arthritis.
Chemical Properties
White Powder
Uses
For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.
Definition
ChEBI: A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.
Indications
Mycophenolate mofetil (MMF, CellCept) is an ester prodrug of mycophenolic acid (MPA), a Penicillium-derived immunosuppressive agent that blocks de novo purine synthesis by noncompetitively inhibiting the enzyme inosine monophosphate dehydrogenase. MPA preferentially suppresses the proliferation of cells, such as T and B lymphocytes, that lack the purine salvage pathway and must synthesize de novo the guanosine nucleotides required for DNA and RNA synthesis.MPA has been used for decades as a systemic treatment for moderate to severe psoriasis. MMF was developed to increase the bioavailability of MPA.
Mechanism of action
the guanosine nucleotides required for DNA and RNA synthesis.MPA has been used for decades as a systemic treatment for moderate to severe psoriasis. MMF was developed to increase the bioavailability of MPA.
Clinical Use
MMF is indicated for the prophylaxis of organ rejection in patients receiving renal, hepatic, and cardiac transplants; it is often used in combination with other immunosuppressive agents for this indication. In dermatology, MMF is particularly useful as monotherapy, or as a steroid-sparing agent, for treatment of autoimmune blistering diseases (bullous pemphigoid and pemphigus). It may also be useful for the treatment of inflammatory skin diseases mediated by neutrophilic infiltration, such as pyoderma gangrenosum, and psoriasis.
Side effects
Adverse effects produced by MMF most commonly include nausea, abdominal cramps, diarrhea, and possibly an increased incidence of viral and bacterial infections. Whether MMF may be associated with an increased long-term risk of lymphoma or other malignancies is controversial; however, any such risk is likely to be lower in patients treated for skin disease with MMF monotherapy than in transplant patients treated with combination immunosuppressive therapy.
Mycophenolate mofetil Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| GLR Innovations | +91 9891111994 | New Delhi, India | 4542 | 58 | Inquiry |
| ChemBioReas Life Sciences | +91-7989264158 +91-7989264158 | Hyderabad, India | 82 | 58 | Inquiry |
| KARPSCHEM LABORATORIES | +91-7249203006 +91-7249203006 | Maharashtra, India | 786 | 58 | Inquiry |
| Solara Active Pharma Sciences Ltd | +91-8046632100 +91-7075706520 | Bangalore, India | 65 | 58 | Inquiry |
| Besil Chem LLP | +91-7760252666 +91-9880731835 | Bangalore, India | 163 | 58 | Inquiry |
| Humble Healthcare Limited | +91-9720093000 +91-8006400378 | Uttar Pradesh, India | 141 | 58 | Inquiry |
| Sumar Biotech LLP | +91-7984183709 +91-9824575381 | Gujarat, India | 22 | 58 | Inquiry |
| Cleargreens Pharmaceutical Private Limited | +91-9879791802 +91-9579898158 | Gujarat, India | 14 | 58 | Inquiry |
| BDR Pharmaceuticals International Pvt Ltd | +91-2240560560 +91-7718884418 | Maharashtra, India | 206 | 58 | Inquiry |
| Rakshit Group of Companies (Rakshit Drugs Pvt Ltd) | +91-4023810385 +91-9246228579 | Telangana, India | 36 | 58 | Inquiry |
128794-94-5(Mycophenolate mofetil)Related Search:
1of4
chevron_right